Tscan therapeutics announces fda clearance of investigational new drug application for tsc-203-a0201 targeting prame

Tsc-203-a0201 is tscan's fourth tcr-t cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed tcr-t cell therapy tsc-203-a0201 is tscan's fourth tcr-t cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed tcr-t cell therapy
TCRX Ratings Summary
TCRX Quant Ranking